There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inovio Pharmaceuticals (INO) and Morphic Holding (MORF) with bullish sentiments.
Inovio Pharmaceuticals (INO)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Inovio Pharmaceuticals yesterday and set a price target of $6.00. The company’s shares closed last Monday at $2.31, close to its 52-week low of $1.92.
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -22.0% and a 25.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $8.25, a 245.2% upside from current levels. In a report issued on November 5, Piper Jaffray also maintained a Buy rating on the stock with a $10.00 price target.
See today’s analyst top recommended stocks >>
Morphic Holding (MORF)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Morphic Holding. The company’s shares closed last Monday at $15.01, close to its 52-week low of $12.03.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 18.2% and a 45.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Morphic Holding with a $30.00 average price target, a 94.8% upside from current levels. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
